These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 10196452)

  • 1. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H; Araki T; Nagasawa H; Itoyama Y
    Brain Res; 1999 Apr; 824(2):224-31. PubMed ID: 10196452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
    Araki T; Mikami T; Tanji H; Matsubara M; Imai Y; Mizugaki M; Itoyama Y
    Eur J Pharm Sci; 2001 Jan; 12(3):231-8. PubMed ID: 11113642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
    Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
    Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of neurotensin receptors in MPTP-treated mice.
    Tanji H; Araki T; Fujihara K; Nagasawa H; Itoyama Y
    Peptides; 1999; 20(7):803-7. PubMed ID: 10477079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA; Rothblat DS; Joyce JN; Schneider JS
    Synapse; 1995 Jan; 19(1):46-55. PubMed ID: 7709343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
    Kuhlmann AC; Guilarte TR
    Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
    Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
    Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
    Cox RF; Waszczak BL
    Brain Res; 1993 Jun; 613(1):32-42. PubMed ID: 8102308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
    Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
    Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C; Gomez-Mancilla B; Bédard PJ; Di Paolo T
    Neurosci Lett; 1993 Nov; 163(1):31-5. PubMed ID: 7905197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dopamine D1 receptor stimulation on the up-regulation of histamine H3-receptors following destruction of the ascending dopaminergic neurones.
    Ryu JH; Yanai K; Zhao XL; Watanabe T
    Br J Pharmacol; 1996 Jun; 118(3):585-92. PubMed ID: 8762081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
    Aoki E; Yano R; Yokoyama H; Kato H; Araki T
    Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic identification of D1 dopamine receptors labelled with [3H]dopamine: distribution, regulation and relationship to coupling.
    Hervé D; Trovero F; Blanc G; Glowinski J; Tassin JP
    Neuroscience; 1992; 46(3):687-700. PubMed ID: 1532052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.
    Goulet M; Morissette M; Calon F; Blanchet PJ; Falardeau P; Bédard PJ; Di Paolo T
    Neuroscience; 1997 Jul; 79(2):497-507. PubMed ID: 9200732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats.
    Araki T; Tanji H; Fujihara K; Kato H; Imai Y; Mizugaki M; Itoyama Y
    J Neural Transm (Vienna); 2000; 107(8-9):873-84. PubMed ID: 11041269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.